PYODERMA GANGRENOSUM
Clinical trials for PYODERMA GANGRENOSUM explained in plain language.
Never miss a new study
Get alerted when new PYODERMA GANGRENOSUM trials appear
Sign up with your email to follow new studies for PYODERMA GANGRENOSUM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug hopes to heal painful skin ulcers in rare disease
Disease control Recruiting nowThis study tests whether spesolimab, given as an infusion, can help close skin ulcers in adults with pyoderma gangrenosum, a rare inflammatory skin condition. About 90 participants will receive either spesolimab or a placebo, along with corticosteroids. The trial lasts about 1.5 …
Matched conditions: PYODERMA GANGRENOSUM
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can a psoriasis drug heal these stubborn skin ulcers?
Disease control Recruiting nowThis study tests guselkumab (Tremfya), a drug already used for psoriasis, in 17 adults with pyoderma gangrenosum—a rare disease that leads to painful, hard-to-heal skin ulcers. Participants receive injections every 4 weeks for 28 weeks. Researchers will check if ulcers heal compl…
Matched conditions: PYODERMA GANGRENOSUM
Phase: PHASE2 • Sponsor: Oregon Health and Science University • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC